查詢結果分析
相關文獻
- 直腸癌病人接受術後單獨放射線治療之治療結果及預後因子
- Postoperative Radiotherapy for Malignant Parotid Gland Tumors
- 直腸癌之放射線治療
- Postoperative Adjuvant Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Treatment Results and Prognostic Factors
- 非小細胞肺癌之手術後放射線治療
- 手術後放射線治療對於輔助性化學療法之影響:第三期乳癌病患的分析
- The Value of FDG PET/CT to Monitor Treatment Response Post ⁹°Y-Microsphere Selective Internal Radiation Therapy in Colorectal Cancer with Hepatic Metastasis: Preliminary Experience in Kaohsiung Medical University Hospital
- 利用分子檢測以FOLFOX4術前化學放射線治療與達文西機械手臂成功治療超低位局部進行期直腸癌
- Gene Sequencing for Selection of Chemotherapy Drugs Combined with Stereotactic Body Radiation Therapy for Stage Ⅳ Colon Cancer: A Case Report
- 補充麩醯胺對於術前化學及放射線治療之直腸癌病人腹瀉的影響
頁籤選單縮合
題 名 | 直腸癌病人接受術後單獨放射線治療之治療結果及預後因子=Adjuvant Postoperative Radiotherapy of Rectal Cancer: An Analysis of Treatment Results and Prognostic Factors |
---|---|
作 者 | 許軒之; 陳鴻華; 王重榮; 黃英彥; 張家駱; 熊敬業; 陳惠君; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 6:3 1999.09[民88.09] |
頁 次 | 頁179-186 |
分類號 | 416.245 |
關鍵詞 | 直腸癌; 手術後放射線治療; 放射線治療; Rectal cancer; Postoperative radiotherapy; Irradiation; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:分析直腸癌病人接受術後單獨放射線治療的治療結果與預後因子。 材料與方法:從1987年10月至1997年8月共95位接受根除性手術的直腸癌病人前來本科接 受術後放射線輔助治療,放射線治療乃採用10或15 MV的X-ray,每週治療五次,每次劑量 1.8至2 Gy不等,總劑量為52~60 Gy,每位病人均至少有兩年的追□。 結果:此95位病人之5年局部控制率、存活率、無遠處轉移率及無病存活率分別為49%、43%、 46%、35%。在預後因子方面,以單變數分析結果顯示期別(Ⅱ vs Ⅲ)、T之分期(T3 vs T4)、 N之分期(NO vs N1 vs N2)以及手術前病人血中CEA值(<5 ng/ml vs ≧5 ng/m|}四項不論在 局部控制率、存活率、無遠處轉移率、及無病存活率均有統計上的差異;但以多變數分析則只 有N之分期於局部控制率(p=0.0124}、存活率{p=0.0014}、無遠處轉移率(p=0.0012)、及無 病存活率《p=0.0010)四項同時有統計上的差異。 結論:N之分期{即腫瘤侵犯淋巴結數目)為接受術後放射線治療之直腸癌病人最重要的預後 因子,腫瘤侵犯淋巴結數目大於3顆者其預後較差,至於應該給予何種輔助治療才能使病人獲 得最大的助益,則有待更進一步的研究。 |
英文摘要 | Purpose: To analyze the treatment results and prognostic factors in rectal cancer patients receiving postoperative radiotherapy after radical resection. Materials and Methods: From October 1987 through August 1997, ninety-five patients with stage II or III (AJCC 1997) rectal cancer were treated with complete surgical resection and postoperative adjuvant pelvic irradiation without chemotherapy. The radiation was delivered with 10 or 15 MV X-ray given 5 days per week at 1.8 to 2 Gy per fraction. Total doses ranged from 52 to 60 Gy. All patients had at least 2 years of follow-up. Results: The 5-year local control rate (LC), overall survival rate (OS), distant metastasis-free rate (DMF) and disease-free survival rate (DFS) for the 95 patients were 49%, 43%, 46% and 35%, respectively. In univariate analysis, the stage (II vs. 111), T stage (T3 vs. T4), N stage (N0 vs. N1 vs. N2) and preoperative CEA (<5 vs. 5≧ ng/ml) were the significant prognostic factors in LC, OS, DMF and DFS. In multivariate analysis, the N stage was the only statistically significant predictor of LC (p= 0.0124), OS (p= 0.0014), DMF (p= 0.0012) and DFS (p=0.0010). Conclusion: N stage (the number of involved nodes) is the most important prognostic factor in rectal cancer patients receiving postoperative radiotherapy alone. Patients with more than 3 involved nodes had significantly poor treatment outcome. The optimal adjuvant treatment for rectal cancer is still controversial. Further investigation of various treatment modalities is needed. |
本系統中英文摘要資訊取自各篇刊載內容。